title: [Adaptation of different modifications of enzyme immunoassay and immune blot assay to assess the candidate vaccine HIVREPOL against HIV/AIDS].
abstract: A preclinical trial of the vaccine HIVREPOL provided a complex of methods for assessing the identity and specific activity of vaccines against HIVIAIDS. The identity of "HIVREPOL" has been assessed by indirect enzyme immunoassay (EIA): the vaccine specifically binds the antibodies of the sera from HIV-infected individuals. Immune blot assay was the most informative method for assessing the identity of the candidate vaccine. The sera from HIVREPOL-vaccinated mice recognized the proteins gp41, p24, p55 of cultured HIV1 on "New-Lay-Blot1" strips. The bands corresponding to p24 were revealed in the line blots "Blot-HIV-1/2+O" and "INNO-LIA-HIV-Confirmation". The specific activity of the HIVREPOL vaccine was confirmed from the reactivity of sera of the mice vaccinated with recombinant proteins of the immunosorbents available in EIA test systems for the detection of HIV antibodies. Competitive EIA established the antigen-binding activity of sera from HIVREPOL-vaccinated mice against the native reference HIV-1 antigen.
authors.forename: T A
authors.initials: TA
authors.lastname: Chekanova
authors.forename: M S
authors.initials: MS
authors.lastname: Vorob'eva
authors.forename: M N
authors.initials: MN
authors.lastname: Rasshchepkina
authors.forename: T A
authors.initials: TA
authors.lastname: Bektemirov
authors.forename: G O
authors.initials: GO
authors.lastname: Gudima
authors.forename: I G
authors.initials: IG
authors.lastname: Sidorovich
authors.forename: I A
authors.initials: IA
authors.lastname: Nikolaeva
authors.forename: S V
authors.initials: SV
authors.lastname: Korobova
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D000818:Animals; D021461:Animals, Outbred Strains; D000918:Antibody Specificity; D015153:Blotting, Western / Q000379:methods*; D004353:Drug Evaluation, Preclinical; D015683:Gene Products, gag / Q000276:immunology; D015483:HIV Antibodies / Q000097:blood / Q000276:immunology*; D015488:HIV Antigens / Q000276:immunology; D016655:HIV Core Protein p24 / Q000276:immunology; D015700:HIV Envelope Protein gp41 / Q000276:immunology; D015658:HIV Infections / Q000097:blood / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007114:Immunization; D007115:Immunization Schedule; D007124:Immunoenzyme Techniques / Q000379:methods*; D007274:Injections, Intraperitoneal; D051379:Mice; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D011498:Protein Precursors / Q000276:immunology; D011933:Reagent Kits, Diagnostic; D012680:Sensitivity and Specificity
chemical_list: D016915:AIDS Vaccines; D015683:Gene Products, gag; D015483:HIV Antibodies; D015488:HIV Antigens; D016655:HIV Core Protein p24; D015700:HIV Envelope Protein gp41; D011498:Protein Precursors; D011933:Reagent Kits, Diagnostic; C059767:p55 gag precursor protein, Human immunodeficiency virus 1